CPNG

Coupang, Inc.

15.04
USD
17.96%
15.04
USD
17.96%
8.98 46.00
52 weeks
52 weeks

Mkt Cap 23.78B

Shares Out 1.58B

Chat
Send me real-time posts from this site at my email

Validea Kenneth Fisher Strategy Daily Upgrade Report - 4/23/2022

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins. ADVANSIX INC (ASIX) is a small-cap value stock in the Chemicals - Plastics & Rubber industry. The rating according to our strategy based on Kenneth Fisher changed from 60% to 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: AdvanSix Inc. is a manufacturer of Nylon 6, a polymer resin which is a synthetic material used by its customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as such as building and construction, fertilizers, plastics, solvents, packaging, paints, coatings, adhesives and electronics. It also sells caprolactam, ammonium sulfate fertilizer, acetone and other intermediate chemicals, all of which are produced within unit operations across its integrated manufacturing value chain. It sells its Nylon 6 resin globally, primarily under the Aegis brand name. In addition, its Nylon 6 resin is used to produce nylon films which it sells to its customers primarily under the Capran brand name. Caprolactam is the key monomer used in the production of Nylon 6 resin. Its Ammonium sulfate fertilizer is derived from the caprolactam manufacturing process and sells ammonium sulfate primarily to North American and South American distributors. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of ADVANSIX INC COUPANG INC (CPNG) is a large-cap value stock in the Retail (Catalog & Mail Order) industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Coupang Inc, formerly Coupang LLC, is a Korea-based company principally engaged in the providing of e-commerce services. The Company mainly provides home goods and decoration, apparel, and beauty products, fresh food and grocery, sporting goods, electronics, restaurant order and delivery, travel and everyday consumables and other products and services. The Company operates e-commerce and logistics system and provides delivery services. In addition, the Company also offers the online advertising space on its websites and mobile applications. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of COUPANG INC MARCUS & MILLICHAP INC (MMI) is a small-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Kenneth Fisher changed from 68% to 90% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Marcus & Millichap, Inc. is a brokerage company specializing in commercial real estate investment sales, financing, research and advisory services. The Company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory and consulting services. It provides its financing services through Marcus & Millichap Capital Corporation. Its research, advisory and consulting services are designed to assist clients in forming their investment strategy and making transaction decisions. Its advisory services include opinions of value, operating and financial performance benchmarking analysis, and specific asset buy-sell strategies. The Company has investment sales and financing professionals in various offices in the United States and Canada that provide investment brokerage and financing services. It provides a range of advisory and consulting services to developer, lenders and pension fund advisors. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of MARCUS & MILLICHAP INC UNIQURE NV (QURE) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Company Description: Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company's lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington's disease is in Phase I/II clinical study. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. Detailed Analysis of UNIQURE NV About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink. About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue